UBS O'Connor’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,576
| Closed | -$31.6K | – | 280 |
|
|
2025
Q1 | $31.6K | Sell |
15,576
-87,208
| -85% | -$177K | ﹤0.01% | 242 |
|
|
2024
Q4 | $619K | Buy |
102,784
+23,535
| +30% | +$142K | 0.02% | 256 |
|
|
2024
Q3 | $555K | Sell |
79,249
-26,000
| -25% | -$182K | 0.01% | 328 |
|
|
2024
Q2 | $610K | Sell |
105,249
-21,700
| -17% | -$126K | 0.02% | 347 |
|
|
2024
Q1 | $908K | Buy |
126,949
+33,506
| +36% | +$240K | 0.03% | 281 |
|
|
2023
Q4 | $460K | Sell |
93,443
-11,557
| -11% | -$56.9K | 0.01% | 349 |
|
|
2023
Q3 | $1M | Buy |
105,000
+5,000
| +5% | +$47.8K | 0.02% | 323 |
|
|
2023
Q2 | $1.3M | Buy |
+100,000
| New | +$1.3M | 0.03% | 353 |
|